Table 4.
Author (year) | N | Ablative agents | Median follow up (months) | CR (%) | CR criteria | Severe complication |
---|---|---|---|---|---|---|
Gan and colleagues (2005)12 | 23 | E | 6–12 | 34.8 | Disappear | 0 |
Dimaio and colleagues (2011)13 | 13 | E | 13.4 | 38.5 | Disappear | 0 |
Oh and colleagues (2011)16 | 47 | E + P | 21.7 (2–44) | 61.7 | <5% volume | 0 |
Caillol and colleagues (2012)10 | 13 | E | 26 (4–118) | 84.6 | Disappear | 0 |
DeWitt and colleagues (2014)15 | 21 | E + P | 27 (17–42) | 47.6 | <5% volume | 4 |
Park and colleagues (2016)9 | 91 | E | 40 (13–117) | 45.1 | Disappear | 0 |
Gomez and colleagues (2016)22 | 23 | E | 45.8 (14.7–90.8) | 8.7 | Disappear | 1 |
Choi and colleagues (2017)14 | 158 | E + P | 69 (48–81) | 72.2 | <5% volume | 1 |
CR, complete remission; E, ethanol; EUS, endoscopic ultrasound; P, paclitaxel.